SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 182,877.37 |
| Enterprise Value ($M) | 202,287.37 |
| Book Value ($M) | 61,704.00 |
| Book Value / Share | 28.41 |
| Price / Book | 2.96 |
| NCAV ($M) | -26,278.00 |
| NCAV / Share | -12.10 |
| Price / NCAV | -6.96 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.25 |
| Return on Assets (ROA) | 0.20 |
| Return on Equity (ROE) | 0.48 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.01 |
| Current Ratio | 1.25 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 37,236.00 |
| Assets | 125,218.00 |
| Liabilities | 63,514.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 52,877.00 |
| Operating Income | 13,036.00 |
| Net Income | 24,021.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 15,071.00 |
| Cash from Investing | 4,208.00 |
| Cash from Financing | -16,264.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | BlackRock Inc. | 5.70 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 117,660 | 1,502,922 | 7.83 | |
| 224,683 | 1,946,266 | 11.54 | |
| 137,265 | 1,774,862 | 7.73 | |
| 149,059 | 1,652,692 | 9.02 | |
(click for more detail) |
|||
(click for list of largest short owners) |
|||
| Similar Companies | |
|---|---|
| MYOV – Myovant Sciences Ltd. | NUVB – Nuvation Bio Inc |
| NVO – Novo-Nordisk A/S | OGN – Organon & Co. |
| PBH – Prestige Brands Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io